All In Biotech

Drug Trial Radar · NCT06271252

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Apr 3, 2024

Primary completion

Dec 12, 2026

Study completion Apr 12, 2028

Sponsor

Lead sponsor
OriCell Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

Conditions

  • Neoplasms, Plasma Cell
  • Neoplasms by Histologic Type
  • Neoplasms
  • Hemostatic Disorders
  • Vascular Diseases
  • Cardiovascular Diseases
  • Paraproteinemias
  • Blood Protein Disorders
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Lymphoproliferative Disorders
  • Immunoproliferative Disorders
  • Immune System Diseases
  • Multiple Myeloma

Interventions

  • OriCAR-017Drug

    Anti-GPRC5D CAR-T cell product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of OriCAR-017 US-P1Time frame: Up to 28 days
  2. Dose-limiting toxicity (DLT)Time frame: Up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northside Hospital

    Atlanta, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.